CN113727988A - 半乳糖凝集素-3的小分子抑制剂 - Google Patents

半乳糖凝集素-3的小分子抑制剂 Download PDF

Info

Publication number
CN113727988A
CN113727988A CN202080030355.9A CN202080030355A CN113727988A CN 113727988 A CN113727988 A CN 113727988A CN 202080030355 A CN202080030355 A CN 202080030355A CN 113727988 A CN113727988 A CN 113727988A
Authority
CN
China
Prior art keywords
compound
disorders
independently
triazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030355.9A
Other languages
English (en)
Chinese (zh)
Inventor
刘春健
D·S·尹
王维
冯建新
B·A·埃尔斯沃思
A·雷盖罗-伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN113727988A publication Critical patent/CN113727988A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080030355.9A 2019-03-26 2020-03-25 半乳糖凝集素-3的小分子抑制剂 Pending CN113727988A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823684P 2019-03-26 2019-03-26
US62/823,684 2019-03-26
PCT/US2020/024548 WO2020198266A1 (en) 2019-03-26 2020-03-25 Small molecule inhibitors of galectin-3

Publications (1)

Publication Number Publication Date
CN113727988A true CN113727988A (zh) 2021-11-30

Family

ID=70293127

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030355.9A Pending CN113727988A (zh) 2019-03-26 2020-03-25 半乳糖凝集素-3的小分子抑制剂

Country Status (7)

Country Link
US (1) US12275719B2 (https=)
EP (1) EP3947407B1 (https=)
JP (1) JP7478165B2 (https=)
KR (1) KR20210143255A (https=)
CN (1) CN113727988A (https=)
ES (1) ES2984075T3 (https=)
WO (1) WO2020198266A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002250A1 (zh) * 2024-06-28 2026-01-02 上海济煜医药科技股份有限公司 四唑基取代的吡喃半乳糖苷衍生物及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230104190A (ko) * 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
JP2024501010A (ja) * 2020-12-28 2024-01-10 ガレクト バイオテック エービー ガレクチンに対する新規ガラクトシド阻害剤
WO2023118267A1 (en) * 2021-12-22 2023-06-29 Galecto Biotech Ab Novel galactoside inhibitor of galectins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
US9021050B2 (en) 2012-08-31 2015-04-28 Yume, Inc. Network service system and method with off-heap caching
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
JP6844991B2 (ja) 2015-11-10 2021-03-17 サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． ジッパーを有する伸縮性衣類の製法
CA3025867A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CA3062648A1 (en) * 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002250A1 (zh) * 2024-06-28 2026-01-02 上海济煜医药科技股份有限公司 四唑基取代的吡喃半乳糖苷衍生物及其制备方法和应用

Also Published As

Publication number Publication date
EP3947407A1 (en) 2022-02-09
KR20210143255A (ko) 2021-11-26
US12275719B2 (en) 2025-04-15
WO2020198266A1 (en) 2020-10-01
EP3947407B1 (en) 2024-06-12
US20220185800A1 (en) 2022-06-16
JP7478165B2 (ja) 2024-05-02
ES2984075T3 (es) 2024-10-28
JP2022527075A (ja) 2022-05-30

Similar Documents

Publication Publication Date Title
EP4271672B1 (en) Carboxy-benzimidazole glp-1r modulating compounds
CN104428299B (zh) 5-氮杂吲唑化合物及其使用方法
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
JP7478165B2 (ja) ガレクチン－３の低分子阻害剤
KR20240127910A (ko) Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물
TW201718536A (zh) 可作為ＴＮＦα調節劑之雜環化合物
CN113710665A (zh) 半乳糖凝集素-3的小分子抑制剂
KR20240075952A (ko) Fgfr 억제제 및 이의 사용 방법
CN112292386B (zh) 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN115109061A (zh) 三环化合物
CN111164084B (zh) 可用作a2a受体拮抗剂的三唑并三嗪衍生物
WO2020162471A1 (ja) ピリドン誘導体
JP7772718B2 (ja) ガレクチン－３阻害剤
EA050465B1 (ru) Соединения карбокси-бензимидазола, модулирующие glp-1r
KR20250166190A (ko) Gpr35 조절제로서 이용하기 위한 이환식 헤테로아릴 화합물
HK40110644A (zh) 具有ent1抑制活性的大环化合物
KR20210100139A (ko) 갈렉틴-3의 소분자 억제제
HK40019785A (en) Triazolotriazine derivatives as a2a receptor antagonists
HK1208439B (zh) 5-氮杂吲唑化合物及其使用方法
HK1233627A1 (en) Serine/threonine kinase inhibitors
HK1233627A (en) Serine/threonine kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination